Email Chinese

The senior management team has, on average, over 15-year combined global pharma/biotech and China domestic pharma leadership experiences in their respective expert areas.

Chairman and Chief Executive Officer: Jingwu Zang, M.D., Ph.D. M.D. (Shanghai JiaoTong University, School of Medicine), Ph.D., Immunology, (University of Brussels), Postdoctoral Fellow, Immunology, (Harvard Medical School, USA), Clinical residency & US physician licensure (TMB-M0983); Academic positions held: Professor, (Baylor College of Medicine, USA); Founding directors for Institute of Health Sciences and Institute Pasteur Shanghai of Chinese Academy of Sciences. Published over 160 papers, including in Science, Nature series, and book chapters in Immune regulation and autoimmune disease. Pharma or biotech positions held: GSK (Corporate SVP, Head, China R&D); Simcere Pharmaceuticals (CSO), BioSciKin Inc. (CEO), Third Venture Biopharma (founder and CEO).

President: Zheru Zhang, Ph.D. Biochemistry, University of Alberta, Canada. Over 20-year Pharma biologics experiences (BMS, J&J and others) and company management/leadership roles. Adjunct professor (Yeehong Business School, Shenyang Pharmaceutical University). Extensive experiences in CMC regulatory with regulatory authorities such as CFDA, FDA, EMA, MFDS, PMDA and TGA. Led or involved 20 biologics INDs and 6 BLAs submissions globally, including the first Mab biosimilar approved in Europe and USA. Key positions held: Vice President (Celltron), CEO (Shanghai JMT-Bio), President (Tasgen).

Head of Research and Development: Joan (Huaqiong) Shen, MD, PhD.Joan obtained PhD in life science and is a licensed physician with board certification in US. She had postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. Being responsible for global clinical development programs cross phase 1-4, she worked in Eli Lilly & Co, Wyeth and Pfizer while in US, and gained rich experiences of working with FDA, EMEA, CFDA, PMDA, KFDA and etc.
Joan was sent by Pfizer in 2011 as the China clinical head. She later joined Hengrui pharmaceutical as the CMO. In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Joan joined I-Mab biopharma as the head of R&D in 2017.
Joan was granted the honor of “Talent of Innovation” by the “National Thousand Talent Program”. She is also elected as the executive committee member of China New Drug Research Evaluation Committee. She holds academic positions as the guest professor of Beijing University Clinical Research Institute and was the adjunctive professor of Indiana University School of Medicine.

Chief Scientific Officer: Taylor Guo, Ph.D. in Immunology (Shanghai JiaoTong University School of Medicine). A decade of discovery and early development experience in neuroimmunology, immuno-oncology and neurodegeneration at Third Venture Biopharma and GSK. Extensive experience in developing facile and robust translatable in vitro and PD assays. Published more than 35 papers.

Vice President, CMC: Doug Chen, Ph.D. in Molecular Genetics, Shanghai Institute of Meteria Medica, Chinese Academy of Science. Postdoctoral fellow and Assistant Professor (Molecular Biology, University of Southern California, School of Medicine). Over 20 scientific publications. 20-year biomedical research and biologics development experience in US and China (Deltagen, Roche, Baxter, Jassen, Yamato, Synthomics, Benemae,Tasgen) with increased technical and management responsibility. Led or involved in >12 biologics development projects (cell line, cell banking, process development, IND filing towards GMP production), which involved antibodies, Fc fusion proteins, growth factors and coagulation factors etc.

Vice President, Pre-Clinical Development: Bruce He, Ph.D. in Toxicology, University of Georgia. Over 15 years of experiences in biopharma and contract research laboratories. Leadership in nonclinical projects of both new chemical entities and biologics (led 15 INDs and 2 NDAs) in US and China. Adjunct associate professor (School of Pharmacy, University of Kansas), diplomate, American Board of Toxicology. Extensive experiences in interacting with global regulatory authorities (US FDA, China FDA, Korean MFDS, and Germany BfArM). Positions held: facility manager (JOINN Laboratories), Senior director, toxicology (WuXi AppTec), Head of pharmacology and toxicology (Biothera and CyDex now Ligand).

Head, Global Regulatory Affairs: Tiffany Liang, Biochemistry, Central University for Nationalities; MBA. Over 10 years of combined regulatory affairs experiences (Beijing Med Pharm, DSM, GSK and Abbott/AbbVie). 5 NDAs including 2 clinical trial waivers and 2 priority reviews in China, 17 INDs/CTAs. Experienced in GCP/GMP inspections, Co-developed 2 guidelines (biologics stability & cell therapy treatment) with CDE; GCE platform establishment for Chinese pharmacopeia.

Head, Clinical Operations: Yin Liu, M.D. (Harbin Medical University), MS in biochemistry and molecular biology (Shanghai JiaoTong University), attending physician (Heilongjiang Fourth People’s Hospital, China), Professor (Chi Nan University, School of Pharmacy). Positions held: Medical Science Director (Tigermed), Senior Director, Clinical & Medical affairs (Henlius), Senior Medical Director (Hansoh).

Head, Company Operations, Secretary of BoD: Lili Qian, Ph.D. in Microbiology, Peking University/Stanford University, Pharma operational experiences, covering Project Management (certified PMP), Fundraising (Series A and Series B), Investor Relations, Human Resources, management of portfolio companies, strategic alliances, Government Affairs (Simcere Pharmaceuticals and BioSciKin). Co-founder of Third Venture Biopharma.

Global Business Development: Sean Cao, Ph.D. in Microbiology, University of Virginia; Post-doctoral fellow, National Institutes of Health; MBA, Warton School of Business, University of Pennsylvania. Over 10-year pharma business development leadership experience (Aventis, J&J, Sanofi, Simcere Pharmaceuticals).

CMC Senior Director: Junhua Qiao, CMC Senior Director, PhD in Molecular Biology, former German National Research Center for Biotechnology; Postdoc fellow, EPFL, Switzerland. Research focus on targeted integration technology and genomic regulatory elements for stable cell line development. 8-year experience of Biologics process development and CMC technical management. Position held: Head of Biologics Research and Development in Hansoh Pharma Group; Director of Cell Line Development in WuXi Biologics, led multiple domestic and international CMC projects towards IND filing; Scientist in Boehringer Ingelheim Germany to develop next generation stable cell line technology. 2014 Rising Star Plan from Shanghai Government, published 7 papers and applied 2 Chinese patents.

Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210    Tel:86-21-6057 8000     Email:marcom@i-mabbiopharma.com